This inventor holds 5 USPTO granted patents and 1 published patent application. Top assignees: Leland Stanford Junior University, Other. Active years: 2000-2019.
Company Filing History:
4 out of 5,497 
1 out of 834,411 Years Active: 2000-2019
Title: The Innovations of Russ B Altman
Introduction
Russ B Altman is a prominent inventor based in Menlo Park, CA. He has made significant contributions to the field of pharmacogenomics and drug interaction analysis. With a total of 5 patents, his work focuses on developing algorithms that enhance the understanding of drug effects and interactions.
Latest Patents
One of his latest patents is titled "Signal detection algorithms to identify drug effects and drug interactions." This invention provides a method for latent signal detection of adverse events. The algorithm infers the presence of adverse drug events from large observational databases maintained by organizations such as the FDA and WHO. Notably, these algorithms do not require explicit reporting of adverse events, instead inferring them through common secondary effects. Machine learning techniques are employed to enhance the accuracy of these detections.
Another significant patent is the "Method and system for extraction and normalization of relationships via ontology induction." This patent describes methods for developing an ontology of pharmacogenomics relationships. It starts from a lexicon of key pharmacogenomic entities and utilizes syntactic parsing to systematically extract relationships. The extracted relationships demonstrate a precision rate of 70-87.7% and involve critical entities such as genes, drugs, and phenotypes.
Career Highlights
Russ B Altman has had a distinguished career, working at Leland Stanford Junior University. His research has significantly impacted the field of pharmacogenomics, providing valuable insights into drug interactions and patient safety.
Collaborations
Throughout his career, Altman has collaborated with notable individuals such as Nicholas Tatonetti and Guy Haskin Fernald. These collaborations have furthered the development of innovative solutions in the realm of drug safety and pharmacogenomics.
Conclusion
Russ B Altman is a key figure in the field of pharmacogenomics, with a focus on improving drug safety through innovative algorithms. His contributions continue to shape the understanding of drug interactions and adverse events, making a lasting impact on healthcare.